Merck acquires VC-backed OncoEthix

Merck has bought Swiss-based OncoEthix, a biotech firm that focuses on developing cancer drugs. The acquisition is being made with an upfront payment of up to $110 million. OncoEthix's backers included Index Ventures, SV Life Sciences, Endeavour Vision and Edmond de Rothschild Investment Partners.

North AmericaUSM&A DealsBriefs